BRAF and melanoma: Additional examples are HER2 inhibition in breast cancer using lapatinib and/or HER2-specific monoclonal antibodies trastuzumab and pertuzumab or BRAF mutated malignant melanoma using the tyrosine kinase inhibitors vemurafenib or dabrafenib (Swain et al., 2015; Jiao et al., 2018).